Synthesis of self-immolative glucuronide spacers based on aminomethylcarbamate. Application to 5-fluorouracil prodrugs for antibody-directed enzyme prodrug therapy

Abstract

The synthesis of three novel potential glucuronide-based prodrugs for antibody-directed enzyme prodrug therapy (ADEPT) is described. These prodrugs were designed to be activated at the tumour site by β-glucuronidase to afford the corrresponding anticancer agent, 5-FU. The structural pattern of these compounds includes a self-immolative spacer between the glucuronyl residue and the N¹ of 5-FU. Three types of spacers have been elaborated which, after enzymic hydrolysis, spontaneously decompose to deliver an unstable N¹ aminal 5-FU derivative and, from there, the cytotoxic drug. All potential prodrugs were stable and proved to be excellent substrates of E. coli in in vitro experiments.

References

1. K. D. Bagshawe, Br. J. Cancer, 1987, 56, 531.
2. I. Niculescu-Duvaz and C. J. Springer, Adv. Drug Deliv. Rev., 1997, 26, 151.
3. K. Bosslet, J. Czech and D. Hoffmann, Cancer Res., 1994, 54, 2151.
4. J.-C. Florent, X. Dong, G. Gaudel, S. Mitaku, C. Monneret, J.-P. Gesson, J.-C. Jacquesy, M. Mondon, B. Renoux, S. Andrianomenjanahary, S. Michel, M. Koch, F. Tillequin, M. Gerken, J. Czech, R. Straub and K. Bosslet, J. Med. Chem., 1998, 41, 3572.
5. K. Bosslet, J. Czech, P. Lorenz, H. H. Sedlacek, M. Schuermann and G. Seemann, Br. J. Cancer, 1992, 65, 234.
6. K. Bosslet, R. Straub, M. Blumrich, J. Czech, M. Gerken, B. Sperker, H. Kroemer, J.-P. Gesson, M. Koch and C. Monneret, Cancer Res., 1998, 58, 1195 and refs. cited therein.
7. C. Heidelberger, N. K. Chauduri, P. Danneberg, M. Mooren, L. Griesbach, R. Duchinsky, R. J. Schnitzer, E. Pleven and L. Scheneider, Nature, 1957, 179, 663; C. E. Myers, Pharmacol. Rev., 1981, 33, 1.
8. P. M. Wallace, J. F. MacMaster, V. F. Smith, D. E. Kerr, P. D. Senter and W. L. Cosand, Cancer Res., 1994, 54, 2719.
9. S. K. Sharma, Adv. Drug Deliv. Rev., 1996, 22, 369.
10. J.-P. Gesson, J.-C. Jacquesy, M. Mondon, P. Petit, B. Renoux, S. Andrianomenjanahary, H. Dufat-Trin-Van, M. Koch, S. Michel, F. Tillequin, J.-C. Florent, C. Monneret, K. Bosslet, J. Czech and D. Hoffmann, Anti-Cancer Drug Des., 1994, 9, 409.
11. W. D. Kingsbury, J. C. Boehm, R. J. Mehta, S. F. Grappel and C. Gilvarg, J. Med. Chem., 1984, 27, 1447.
12. D. Putnam and J. Kopeck, Bioconjugate Chem., 1995, 6, 483.
13. A. Gledhill, C. J. McCall and M. D. Threadgill, J. Org. Chem., 1986, 51, 3196.
14. G. Apitz and W. Steglich, Tetrahedron Lett., 1991, 32, 3163.
15. C. Kolar, H. Moldenhauer and G. Kneissl, J. Carbohydr. Chem., 1990, 9, 571.
16. G. N. Bollenback, J. W. Long, D. G. Benjamin and J. A. Lindquist, J. Am. Chem. Soc., 1995, 77, 3310.